Strongbridge Bio Ord (SBBP) Stock Price, Quote, News and Overview
NASDAQ:SBBP - Nasdaq -
SBBP Quote, Performance and Key Statistics
2
+0.03 (+1.52%)
The current stock price of SBBP is 2 null. In the past month the price decreased by -8.68%. In the past year, price decreased by -11.5%.
SBBP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About SBBP
Company Profile
Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. The company is headquartered in Trevose, Pennsylvania and currently employs 72 full-time employees. The company went IPO on 2015-09-10. The firm is focused on the development and commercialization of therapies for a range of diseases. The firm's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The firm has a clinical-stage pipeline of therapies for endocrine diseases. The firm's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The firm is studying COR-003 for the treatment of endogenous Cushing's syndrome. The company is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
Company Info
Strongbridge Bio Ord
900 Northbrook Dr Ste 200
Trevose PENNSYLVANIA 19053 US
CEO: John H. Johnson
Employees: 72
Company Website: http://www.strongbridgebio.com/
Phone: 16102549200.0
Strongbridge Bio Ord / SBBP FAQ
What is the stock price of Strongbridge Bio Ord today?
The current stock price of SBBP is 2 null. The price increased by 1.52% in the last trading session.
What is the ticker symbol for Strongbridge Bio Ord stock?
The exchange symbol of Strongbridge Bio Ord is SBBP and it is listed on the Nasdaq exchange.
On which exchange is SBBP stock listed?
SBBP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Strongbridge Bio Ord stock?
4 analysts have analysed SBBP and the average price target is 5.1 null. This implies a price increase of 155% is expected in the next year compared to the current price of 2. Check the Strongbridge Bio Ord stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Strongbridge Bio Ord worth?
Strongbridge Bio Ord (SBBP) has a market capitalization of 135.66M null. This makes SBBP a Micro Cap stock.
How many employees does Strongbridge Bio Ord have?
Strongbridge Bio Ord (SBBP) currently has 72 employees.
What are the support and resistance levels for Strongbridge Bio Ord (SBBP) stock?
Strongbridge Bio Ord (SBBP) has a support level at 1.95 and a resistance level at 2.05. Check the full technical report for a detailed analysis of SBBP support and resistance levels.
Is Strongbridge Bio Ord (SBBP) expected to grow?
The Revenue of Strongbridge Bio Ord (SBBP) is expected to grow by 25.01% in the next year. Check the estimates tab for more information on the SBBP EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy Strongbridge Bio Ord (SBBP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SBBP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SBBP, evaluating the profitability, health, valuation and growth aspects
- Strongbridge Bio Ord (SBBP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Strongbridge Bio Ord (SBBP) Sales and EPS estimates to see what analysts future expectations are.
- Strongbridge Bio Ord (SBBP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Strongbridge Bio Ord (SBBP) Insider and Institutional Ownership to learn about the owners and their transactions.
- Strongbridge Bio Ord (SBBP) Stock Chart to make your own analysis
- Strongbridge Bio Ord (SBBP) Latest news and press-releases to stay up to date.
Does Strongbridge Bio Ord (SBBP) stock pay dividends?
SBBP does not pay a dividend.
When does Strongbridge Bio Ord (SBBP) report earnings?
Strongbridge Bio Ord (SBBP) will report earnings on 2022-03-02, before the market open.
What is the Price/Earnings (PE) ratio of Strongbridge Bio Ord (SBBP)?
Strongbridge Bio Ord (SBBP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.41).
SBBP Technical Analysis
SBBP Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to SBBP. SBBP has a bad profitability rating. Also its financial health evaluation is rather negative.
SBBP Financial Highlights
Over the last trailing twelve months SBBP reported a non-GAAP Earnings per Share(EPS) of -0.41. The EPS increased by 49.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -115.66% | ||
| ROA | -41.48% | ||
| ROE | N/A | ||
| Debt/Equity | 0.38 |
SBBP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to SBBP. The Buy consensus is the average rating of analysts ratings from 4 analysts.
For the next year, analysts expect an EPS growth of 35.78% and a revenue growth 25.01% for SBBP